Tectonic Therapeutic (TECX) Stock Forecast & Price Target

Compare

551 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

TECX Analyst Ratings

Strong Buy

7 Buy

0 Hold

0 Sell

Based on 7 analysts giving stock ratings to

Tectonic

Therapeutic

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

TECX Stock 12 Month Forecast

Average Price Target

$83.60

▲(278.11% Upside)

Based on 7 Wall Street analysts offering 12 month price targets for Tectonic Therapeutic in the last 3 months. The average price target is $83.60 with a high forecast of $101.00 and a low forecast of $69.00. The average price target represents a 278.11% change from the last price of $22.11.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"14":"$14","36":"$36","58":"$58","80":"$80","102":"$102"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":101,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$101.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":83.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$83.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":69,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$69.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[14,36,58,80,102],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20.73,26.904615384615383,33.07923076923077,39.253846153846155,45.428461538461534,51.60307692307693,57.777692307692305,63.952307692307684,70.12692307692308,76.30153846153846,82.47615384615385,88.65076923076923,94.8253846153846,{"y":101,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20.73,25.566153846153846,30.40230769230769,35.238461538461536,40.074615384615385,44.910769230769226,49.74692307692307,54.583076923076916,59.419230769230765,64.25538461538461,69.09153846153845,73.9276923076923,78.76384615384615,{"y":83.6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20.73,24.443076923076923,28.156153846153845,31.869230769230768,35.582307692307694,39.29538461538462,43.00846153846154,46.72153846153846,50.434615384615384,54.14769230769231,57.860769230769236,61.57384615384615,65.28692307692307,{"y":69,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":15.9,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.77,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.2,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.88,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.33,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.17,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.14,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.28,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.84,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.66,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.01,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.16,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.73,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$101.00

Average Price Target$83.60

Lowest Price Target$69.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

David Risinger

Leerink Partners

$69

Buy

212.08%

Upside

Reiterated

08/11/25

Tectonic Therapeutic's Strategic Expansion and Financial Stability Justify Buy Rating

Danielle Brill

Truist Financial

―

Buy

―

Reiterated

08/08/25

Analysts Are Bullish on Top Healthcare Stocks: Tectonic Therapeutic (TECX), Ascend Wellness Holdings LLC (AAWH)

Cory Jubinville, PhD

LifeSci Capital

$87

Buy

293.49%

Upside

Reiterated

08/08/25

Tectonic Therapeutic's Strategic Advancements and Promising Pipeline Drive Buy RatingAer the close, Tectonic Therapeuc (Nasdaq: TECX) reported Q2 2025 earnings and provided key corporate updates.

Uy Ear

Mizuho Securities

$85

Buy

284.44%

Upside

Reiterated

08/08/25

Analysts' Top Healthcare Picks: Stereotaxis (STXS), Tectonic Therapeutic (TECX)

Tiago Fauth

Wells Fargo

$101

Buy

356.81%

Upside

Reiterated

08/07/25

Analysts Are Bullish on These Healthcare Stocks: Ascendis Pharma (ASND), Iovance Biotherapeutics (IOVA)We rate shares Overweight.

Tyler Van Buren

TD Cowen

―

Buy

―

Reiterated

08/07/25

TD Cowen Sticks to Their Buy Rating for Tectonic Therapeutic (TECX)

Martin Auster

Raymond James

$76

Buy

243.74%

Upside

Initiated

06/10/25

Tectonic Therapeutic resumed with an Outperform at Raymond JamesTectonic Therapeutic resumed with an Outperform at Raymond James

Yasmeen Rahimi

Piper Sandler

$76

Buy

243.74%

Upside

Reiterated

05/09/25

Piper Sandler Remains a Buy on Tectonic Therapeutic (TECX)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

David Risinger

Leerink Partners

$69

Buy

212.08%

Upside

Reiterated

08/11/25

Tectonic Therapeutic's Strategic Expansion and Financial Stability Justify Buy Rating

Danielle Brill

Truist Financial

―

Buy

―

Reiterated

08/08/25

Analysts Are Bullish on Top Healthcare Stocks: Tectonic Therapeutic (TECX), Ascend Wellness Holdings LLC (AAWH)

Cory Jubinville, PhD

LifeSci Capital

$87

Buy

293.49%

Upside

Reiterated

08/08/25

Tectonic Therapeutic's Strategic Advancements and Promising Pipeline Drive Buy RatingAer the close, Tectonic Therapeuc (Nasdaq: TECX) reported Q2 2025 earnings and provided key corporate updates.

Uy Ear

Mizuho Securities

$85

Buy

284.44%

Upside

Reiterated

08/08/25

Analysts' Top Healthcare Picks: Stereotaxis (STXS), Tectonic Therapeutic (TECX)

Tiago Fauth

Wells Fargo

$101

Buy

356.81%

Upside

Reiterated

08/07/25

Analysts Are Bullish on These Healthcare Stocks: Ascendis Pharma (ASND), Iovance Biotherapeutics (IOVA)We rate shares Overweight.

Tyler Van Buren

TD Cowen

―

Buy

―

Reiterated

08/07/25

TD Cowen Sticks to Their Buy Rating for Tectonic Therapeutic (TECX)

Martin Auster

Raymond James

$76

Buy

243.74%

Upside

Initiated

06/10/25

Tectonic Therapeutic resumed with an Outperform at Raymond JamesTectonic Therapeutic resumed with an Outperform at Raymond James

Yasmeen Rahimi

Piper Sandler

$76

Buy

243.74%

Upside

Reiterated

05/09/25

Piper Sandler Remains a Buy on Tectonic Therapeutic (TECX)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Tectonic Therapeutic

1 Month

xxx

Success Rate

7/7 ratings generated profit

Average Return

+18.59%

reiterated a xxx

rating 6 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 100.00% of your transactions generating a profit, with an average return of +18.59% per trade.

3 Months

xxx

Success Rate

5/7 ratings generated profit

Average Return

+44.31%

reiterated a xxx

rating 6 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 71.43% of your transactions generating a profit, with an average return of +44.31% per trade.

1 Year

Tyler Van BurenTD Cowen

Success Rate

6/7 ratings generated profit

Average Return

+3.66%

reiterated a buy rating 6 days ago

Copying Tyler Van Buren's trades and holding each position for 1 Year would result in 85.71% of your transactions generating a profit, with an average return of +3.66% per trade.

2 Years

xxx

Success Rate

6/7 ratings generated profit

Average Return

+5.39%

reiterated a xxx

rating 6 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 85.71% of your transactions generating a profit, with an average return of +5.39% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

TECX Analyst Recommendation Trends

Rating

Apr 25

May 25

Jun 25

Jul 25

Aug 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, TECX has received 9 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. TECX average Analyst price target in the past 3 months is 83.60.

Each month's total comprises the sum of three months' worth of ratings.

TECX Financial Forecast

TECX Earnings Forecast

Next quarter’s earnings estimate for TECX is -$1.06 with a range of -$1.15 to -$0.90. The previous quarter’s EPS was -$1.07. TECX beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.33% of the time in the same period. In the last calendar year TECX has Outperformed its overall industry.

No data currently available

TECX Sales Forecast

Next quarter’s sales forecast for TECX is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. TECX beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.46% of the time in the same period. In the last calendar year TECX has Preformed in-line its overall industry.

TECX Stock Forecast FAQ

What is TECX’s average 12-month price target, according to analysts?

Based on analyst ratings, Tectonic Therapeutic’s 12-month average price target is 83.60.

What is TECX’s upside potential, based on the analysts’ average price target?

Tectonic Therapeutic has 278.11% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is TECX a Buy, Sell or Hold?

Tectonic Therapeutic has a consensus rating of Strong Buy which is based on 7 buy ratings, 0 hold ratings and 0 sell ratings.

What is Tectonic Therapeutic’s price target?

The average price target for Tectonic Therapeutic is 83.60. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $101.00 ,the lowest forecast is $69.00. The average price target represents 278.11% Increase from the current price of $22.11.

What do analysts say about Tectonic Therapeutic?

Tectonic Therapeutic’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.

How can I buy shares of TECX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Tectonic Therapeutic (TECX) Stock Forecast & Price Target

TECX Analyst Ratings

TECX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Tectonic Therapeutic

TECX Analyst Recommendation Trends

TECX Financial Forecast

TECX Earnings Forecast

TECX Sales Forecast

TECX Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts